EGFR and non-small cell lung carcinoma: Several tyrosine kinase inhibitors that target EGFR, such as geftinib, have been shown to enhance the inhibitory effect of cisplatin through disruption of the EGFR signaling cascade, and improve survival of NSCLC patients receiving platinum-based chemotherapy [2,3].